Analysts Set Royalty Pharma plc (NASDAQ:RPRX) Price Target at $41.67

Shares of Royalty Pharma plc (NASDAQ:RPRX) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $41.67.

Several brokerages have issued reports on RPRX. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. Citigroup decreased their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th.

Royalty Pharma Stock Up 2.6 %

Shares of RPRX opened at $24.92 on Wednesday. The stock has a 50 day moving average price of $26.43 and a 200 day moving average price of $27.15. Royalty Pharma has a one year low of $24.05 and a one year high of $31.66. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The stock has a market capitalization of $14.68 billion, a price-to-earnings ratio of 12.91, a PEG ratio of 4.36 and a beta of 0.46.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th were issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 3.37%. The ex-dividend date of this dividend was Friday, November 15th. Royalty Pharma’s payout ratio is currently 43.52%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RPRX. Aurora Investment Counsel lifted its holdings in Royalty Pharma by 1.0% in the third quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company’s stock valued at $1,427,000 after acquiring an additional 512 shares during the last quarter. Xponance Inc. raised its position in Royalty Pharma by 1.9% in the second quarter. Xponance Inc. now owns 31,704 shares of the biopharmaceutical company’s stock valued at $836,000 after purchasing an additional 606 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 655 shares during the last quarter. Values First Advisors Inc. lifted its stake in shares of Royalty Pharma by 7.6% in the 3rd quarter. Values First Advisors Inc. now owns 10,412 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 738 shares during the last quarter. Finally, M&T Bank Corp grew its holdings in shares of Royalty Pharma by 4.3% during the 3rd quarter. M&T Bank Corp now owns 18,749 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 779 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.